Zusammenfassung
Die Infusionschemotherapie über die Leberarterie ist heute eine der am häufigsten angewandten Methoden im Bereich der regionalen Chemotherapie. Insbesondere bei der Behandlung von Lebermetastasen von kolorektalen Karzinomen war diese Methode bis zur Etablierung der neuesten Standardtherapie – die systemische Chemotherapie in Kombination mit Irinotecan oder Oxaliplatin – als wirksamste Behandlungsmethode anerkannt. Die meisten randomisierten Studien zum Vergleich der Infusionschemotherapie über die Leberarterie mit der systemischen Chemotherapie konnten jedoch keinen Vorteil in Bezug auf eine Verlängerung des Überlebens belegen [1–12], wobei sich im Bereich der systemischen Chemotherapie die wirksamen systemischen Chemotherapieschemata wie FOLFOX und FOLFIRI als Standard etabliert haben. Infolgedessen spielt die Infusionschemotherapie über die Leberarterie zum jetzigen Zeitpunkt nur noch eine geringe Rolle und wird lediglich unter sehr restriktiven Bedingungen eingesetzt.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Kemeny MM, Goldberg DA, Browning S, Metter GE, et al. Experience with continuous regional chemotherapy and hepatic resection as treatment of hepatic metastases from colorectal primaries. A prospective randomized study. Cancer. 1985;55:1265–70.
Chang AE, Schneider PD, Sugarbaker PH, et al. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg. 1987;206: 685–93.
Kemeny N, Daly J, Reichman B, Geller N, et al. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med. 1987;107:459–65.
Hohn DC, Stagg RJ, Friedman MA, Hannigan Jr JF, et al. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol. 1989;7: 1646–54.
Martin JK, O'Connell MJ, Wieand HS, Fitzgibbons Jr RJ, et al. Intra-arterial floxuridine vs. systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. Arch Surg. 1990;125:1022–7.
Rougier P, Laplanche A, Huguier M, Hay JM, et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol. 1992;10: 1112–8.
Allen-Mersh TG, Earlam S, Fordy C, et al. Quality of life and survival with continuous hepaticartery floxuridine infusion for colorectal liver metastases. Lancet. 1994;344: 1255–60.
Lorenz M, Muller HH. Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2000;18:243–54.
Allen-Mersh TG, Glover C, Fordy C, et al. Randomized trial of regional plus systemic fluorinated pyrimidine compared with systemic fluorinated pyrimidine in treatment of colorectal liver metastases. Eur J Surg Oncol. 2000;26: 468–73.
Kerr DJ, McArdle CS, Ledermann J, et al. Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. Lancet. 2003;361:368–73.
Begos DG, Ballantyne GH. Regional chemotherapy for colorectal liver metastases: thirty years without patient benefit. J Surg Oncol. 1994;56:139–44.
Meta-analysis Group of Cancer. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst. 1996;88:252–8.
Arai Y, Inaba Y, Takeuchi Y. Interventional techniques for hepatic arterial infusion chemotherapy. In: Wilfrido R, Castaneda-Zuniga, editors. Interventional radiology. Baltimore: Williams and Wilkins; 1997. p. 192–205.
Arai Y, Takeuchi Y, Inaba Y, et al. Percutaneous catheter placement for hepatic arterial infusion chemotherapy. Tech Vasc Interv Radiol. 2007;10:30–7.
Ganeshan A, Upponi S, Hon LQ, et al. Hepatic arterial infusion of chemotherapy: the role of diagnostic and interventional radiology. Ann Oncol. 2008;19:847–51.
Kemeny N, Jarnagin W, Paty P, et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol. 2005; 23: 4888–96.
Ducreux M, Ychou M, Laplanche A, et al. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol. 2005;23:4881–7.
Obi S, Yoshida H, Toune R, et al. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer. 2006;106:1990–7.
Seki H, Ozaki T, Takaki S, et al. Using slow-infusion MR arteriography and an implantable port system to assess drug distribution at hepatic arterial infusion chemotherapy. AJR Am J Roentgenol. 2003;180:681–6.
Seki H, Kimura M, Yoshimura N, et al. Hepatic arterial infusion chemotherapy using percutaneous catheter placement with an implantable port: assessment of factors affecting patency of the hepatic artery. Clin Radiol. 1999;54:221–7.
Yamagami T, Iida S, Kato T, et al. Using n-butyl cyanoacrylate and the fixed-catheter-tip technique in percutaneous implantation of a port-catheter system in patients undergoing repeated hepatic arterial chemotherapy. AJR Am J Roentgenol. 2002;179:1611–7.
Tanaka T, Arai Y, Inaba Y, et al. Radiologic placement of side-hole catheter with tip fixation for hepatic arterial infusion chemotherapy. J Vasc Interv Radiol. 2003;14: 63– 8.
Arai Y, Inaba Y, Takeuchi Y, et al. Intermittent hepatic arterial infusion of high-dose 5FU on a weekly schedule for liver metastases from colorectal cancer. Cancer Chemother Pharmacol. 1997;40:526–30.
Arai Y, Inaba Y, Matsueda K, et al. Weekly 5 hour hepatic arterial infusion of high dose 5-FU for unresectable liver metastases from colorectal cancer in patients without extra-hepatic lesions. Proc ASCO. 1998;17:285a.
Arai Y, Sone Y, Tohyama N, et al. Hepatic arterial infusion for unresectable liver metastases from gastric cancer. Proc ASCO. 1992;11:176.
Kumada T, Arai Y, Itoh K, et al. Phase II study of combined administration of 5-fluorouracil, epirubicin and mitomycin- C by hepatic artery infusion in patients with liver metastases of gastric cancer. Oncology. 1999;57:216–23.
Takizawa K, Shimamoto H, Ogawa Y, et al. Development of a new subclavian arterial infusion chemotherapy method for locally or recurrent advanced breast cancer using an implanted catheter-port system after redistribution of arterial tumor supply. Cardiovasc Intervent Radiol. 2009;32:1059–66.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Arai, Y. (2013). Interventionell radiologische Verfahren zur Portkatheter- Implantation. In: Aigner, K.R., Stephens, F.O., Vogl, T.J., Padberg, W. (eds) Regionale Therapie maligner Tumoren. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-35014-6_7
Download citation
DOI: https://doi.org/10.1007/978-3-642-35014-6_7
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-35013-9
Online ISBN: 978-3-642-35014-6
eBook Packages: Medicine (German Language)